Assenagon Asset Management S.A. Sells 191,757 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Assenagon Asset Management S.A. lessened its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 32.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 399,922 shares of the biotechnology company's stock after selling 191,757 shares during the period. Assenagon Asset Management S.A. owned 0.17% of ADMA Biologics worth $7,934,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Mark Sheptoff Financial Planning LLC bought a new position in ADMA Biologics in the 4th quarter worth approximately $35,000. Vision Financial Markets LLC bought a new stake in shares of ADMA Biologics during the 4th quarter valued at $51,000. Farther Finance Advisors LLC raised its position in shares of ADMA Biologics by 1,149.1% during the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after acquiring an additional 2,505 shares during the last quarter. AlphaQuest LLC bought a new stake in shares of ADMA Biologics during the 4th quarter valued at $84,000. Finally, GF Fund Management CO. LTD. bought a new stake in shares of ADMA Biologics during the 4th quarter valued at $85,000. Institutional investors own 75.68% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Finally, Raymond James upped their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $24.25.

ADMA Biologics Stock Down 3.7%

NASDAQ ADMA traded down $0.79 on Friday, reaching $20.81. The company had a trading volume of 2,765,499 shares, compared to its average volume of 3,678,450. The firm has a market capitalization of $4.97 billion, a price-to-earnings ratio of 74.32 and a beta of 0.47. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 1-year low of $10.21 and a 1-year high of $25.67. The company's fifty day moving average is $20.94 and its 200-day moving average is $18.87.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The company had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. ADMA Biologics's revenue for the quarter was up 40.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.08 earnings per share. On average, research analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Lawrence P. Guiheen sold 7,779 shares of the firm's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $20.32, for a total transaction of $158,069.28. Following the transaction, the director now directly owns 114,830 shares of the company's stock, valued at approximately $2,333,345.60. This trade represents a 6.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the transaction, the director now directly owns 478,194 shares in the company, valued at $10,190,314.14. This represents a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 39,000 shares of company stock worth $814,936 over the last three months. Insiders own 3.50% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.